{"doi":"10.1016/j.jdiacomp.2007.03.010","title":"The effect of venlafaxine HCl on painful peripheral diabetic neuropathy in patients with type 2 diabetes mellitus","abstract":null,"journal":"Journal of Diabetes and its Complications","year":2008,"id":684542,"datarank":0.6573039952010823,"base_score":4.382026634673881,"endowment":4.382026634673881,"self_citation_contribution":0.6573039952010823,"citation_network_contribution":0.0,"self_endowment_contribution":0.6573039952010823,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":79,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1788363,"name":"Dede Sit","orcid":null,"position":1,"is_corresponding":false},{"id":1788365,"name":"Hasan Kayabasi","orcid":null,"position":2,"is_corresponding":false},{"id":1788367,"name":"Alpaslan Kemal Tuzcu","orcid":null,"position":3,"is_corresponding":false},{"id":1788368,"name":"Nebahat Tasdemir","orcid":null,"position":4,"is_corresponding":false},{"id":1788371,"name":"M. Emin Yilmaz","orcid":null,"position":5,"is_corresponding":false},{"id":1788362,"name":"Ali Kemal Kadiroglu","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"The effect of venlafaxine HCl on painful peripheral diabetic neuropathy in patients with type 2 diabetes mellitus","abstract":"<h4>Objective</h4>The objective of this study was to evaluate the efficacy of venlafaxine HCl in the symptomatic treatment of painful peripheral diabetic neuropathy (PPDN) among patients with type 2 diabetes mellitus (DM).<h4>Design</h4>This study was designed as a prospective, randomized, and controlled trial.<h4>Setting</h4>This study was conducted at the Dicle University Medical Faculty (Diyarbakir, Turkey).<h4>Patients</h4>Sixty type 2 DM outpatients (47 females and 13 males) with PPDN who had a minimum visual analog scale (VAS) score of 40 mm were enrolled in this study.<h4>Interventions</h4>Patients randomized to the treatment group (n=30) received venlafaxine HCl, whereas those randomized to the control group (n=30) received a combination of vitamins B(1)and B(6) tablets.<h4>Measures</h4>Severity of pain was measured by VAS, Short-Form McGill Pain Questionnaire, and numerical analog scale scores at admission and at the second, fourth, and eighth weeks of the study. Polyneuropathy was supported by electromyelography.<h4>Outcome</h4>In the treatment group, severity of pain was measured as 70.0+/-13.0 in the VAS, as 24.9+/-6.2 in the Short-Form McGill Pain Questionnaire, and as 7.2+/-1.1 in the numerical analog scale. In the control group, it was measured as 73.0+/-8.0 in the VAS, as 26.8+/-6.2 in the Short-Form McGill Pain Questionnaire, and as 7.4+/-0.8 in the numerical analog scale (P>.05).<h4>Results</h4>The most common form of PPDN was distal symmetrical sensorimotor polyneuropathy in both groups (46.8% vs. 50.0%). At the end of the study, there was a significant difference in severity of pain between the groups. In the treatment group, scores were 8.5+/-5.2 and 3.1+/-1.6 in the Short-Form McGill Pain Questionnaire and numerical analog scale, respectively; in the control group, these were 20.5+/-7.0 and 5.5+/-1.6, respectively (P<.001).<h4>Conclusions</h4>Venlafaxine HCl is a safe and well-tolerable analgesic drug in the symptomatic treatment of PPDN; however, it has minimal adverse effects. It showed its efficacy markedly in the second week of therapy.","is_dataset_classified":null,"base_score":4.382026634673881,"endowment":4.382026634673881,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"18413214","pmcid":null,"openalex_id":"https://openalex.org/W2146780921","authors":[],"funders":[],"total_grants":0,"fwci":3.3505,"citation_percentile":0.92399217,"influential_citations":0,"citation_trend":[{"year":2012,"count":8},{"year":2013,"count":13},{"year":2014,"count":5},{"year":2015,"count":4},{"year":2016,"count":5},{"year":2017,"count":3},{"year":2018,"count":4},{"year":2020,"count":2},{"year":2021,"count":7},{"year":2022,"count":4},{"year":2023,"count":1},{"year":2024,"count":2},{"year":2026,"count":1}],"oa_status":"closed","license":"https://www.elsevier.com/tdm/userlicense/1.0/","oa_locations":[{"url":"https://api.elsevier.com/content/article/PII:S1056872707000384?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S1056872707000384?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.jdiacomp.2007.03.010","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/18413214","host_type":"repository"}],"fields_of_study":["Pain Mechanisms and Treatments","Botulinum Toxin and Related Neurological Disorders","Cancer Treatment and Pharmacology","Aged","Analgesics","Cyclohexanols","Diabetes Mellitus, Type 2","Diabetic Neuropathies","Female","Humans","Male","Middle Aged","Pain","Pain Measurement","Prospective Studies","Treatment Outcome","Turkey","Venlafaxine Hydrochloride"],"mesh_terms":["Venlafaxine Hydrochloride","Aged","Analgesics","Cyclohexanols","Diabetes Mellitus, Type 2","Diabetic Neuropathies","Female","Humans","Male","Middle Aged","Pain","Pain Measurement","Prospective Studies","Turkey","Treatment Outcome"],"keywords":["Medicine","Visual analogue scale","McGill Pain Questionnaire","Peripheral neuropathy","Diabetes mellitus","Venlafaxine","Randomized controlled trial","Polyneuropathy","Type 2 Diabetes Mellitus","Type 2 diabetes","Internal medicine","Anesthesia","Surgery","Endocrinology"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-18T14:23:45.200060Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}